Jefferies analyst Jack Slevin raised the firm’s price target on Pediatrix Medical (MD) to $18 from $14 and keeps a Buy rating on the shares. The company “showed strength on all fronts” in Q3, including EBITDA, free cash flow and same-store trends, the analyst tells investors. Despite the move higher, the stock “remains cheap given a best-in-class FCF profile & tangible earnings improvement opportunities,” the analyst argues in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Medical price target raised to $15 from $10 at Leerink
- Pediatrix Medical price target raised to $16 from $13 at Truist
- Pediatrix Medical price target raised to $15 from $9 at Deutsche Bank
- Pediatrix Medical price target raised to $15 from $13 at Mizuho
- Pediatrix Medical Group’s Financial Highlights and Future Plans